Table 1 Antibiotics for treating patients with intra-abdominal infections based upon susceptibility. Use local antibiogram data for choosing optimal antibiotics in target population
Antibiotic | Enterococci | Ampicillin-resistant enterococci | Vancomycin-resistant enterococci | Enterobacteriaceae | ESBL-producing Enterobactericeae | Pseudomonas aeruginosa | Anaerobic Gram-negative bacilli |
|---|---|---|---|---|---|---|---|
Penicillins/Beta-lactamase Inhibitors | |||||||
Amoxicillin/clavulanate | + | − | − | + | − | − | + |
Ampicillin/Sulbactam | + | − | − | + | − | − | +/− |
Piperacillin/tazobactam | + | − | − | + | +/− | + | + |
Carbapenems | |||||||
Ertapenem | − | − | − | + | + | − | + |
Imipenem/cilastatin | +/−a | − | − | + | + | + | + |
Meropenem | − | − | − | + | + | + | + |
Doripenem | − | − | − | + | + | + | + |
Fluoroquinolones | |||||||
Ciprofloxacin | − | − | − | + | − | +b | − |
Levofloxacin | +/− | − | − | + | − | +/− | − |
Moxifloxacin | +/− | − | − | + | − | − | +/− |
Cephalosporins | |||||||
Ceftriaxone | − | − | − | + | − | − | − |
Ceftazidime | − | − | − | + | − | + | − |
Cefepime | − | − | − | + | +/− | + | − |
Ceftolozane/tazobactam | − | − | − | + | + | + | − |
Ceftazidime/avibactam | − | − | − | + | + | + | − |
Aminoglycosides | |||||||
Amikacin | c | c | c | + | + | + | |
Gentamicin | c | c | c | + | + | + | − |
Glycylcyclines | |||||||
Tigecycline | + | + | + | +d | + | − | + |
5-nitroimidazole | |||||||
Metronidazole | − | − | − | − | − | − | + |
Polymyxin | |||||||
Colistimethate (Colistin) | − | − | − | +e | + | + | − |
Glycopeptides | |||||||
Teicoplanin | + | + | − | − | − | − | − |
Vancomycin | + | + | − | − | − | − | − |
Oxazolidines | |||||||
Linezolid | + | + | + | − | − | − | − |